Clinical TrialID 8248
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
NCT05852730
Motion Sickness, Space|Motion Simulation|Parabolic Flight
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 8248
- Evidence Id
- 8248
- Core Evidence Id
- 8248
- Source Clinical Trial Id
- 8246
- Herb2 Clinical Trial Id
- HBCT008246
- Nct Id
- NCT05852730
- Title
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
- Status
- Recruiting
- Phase
- Phase 2
- Study Result
- No
- Study Condition
- Motion Sickness, Space|Motion Simulation|Parabolic Flight
- Study Type
- Interventional
- Study Design
- Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: DPI-386 Nasal Gel|DRUG: Other (e.g., promethazine, meclizine)
- Intervention Allocation
- Non_Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 80
- Outcome Measure
- Motion sickness (MS) symptoms using Pensacola Diagnostic Index (PDI) nausea scale., The maximum nausea score (from 0 = none to 3 = severe) will be recorded once for each of the first three inflight days and once for each of the first three postflight days, or once per operational setting not involving spaceflight (e.g., once per simulation or parabolic flight)., 1 week
- Sponsor Collaborator
- Repurposed Therapeutics, Inc.|National Aeronautics and Space Administration (NASA)
- Funded By
- INDUSTRY
- Location
- NASA Johnson Space Center Neuroscience Laboratory, Houston, Texas, 77058, United States
- Other Id
- NASA 0354 (Aim 2)
- Start Date
- 2021-08-10
- Primary Completion Date
- 2026-09
- Completion Date
- 2026-09
- First Posted
- 2023-05-10
- Results First Posted
- Last Update Posted
- 2024-05-16
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT05852730
- Title Cn
- Title En
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
- Bilingual Status
- semi_complete